Bristol-Myers’ tight-lipped pass on accelerated lung cancer drug approval leaves field wide open for Merck By: MarketWatch January 20, 2017 at 11:11 AM EST The announcement sent Bristol shares plummeting nearly 10%, with Merck stock gaining nearly 4%. Read More >> Related Stocks: Astrazeneca Plc ADR Bristol-Myers Squibb Merck & Co